Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|October 21, 2022

Recipharm to Add High-Speed Filling Line to Wasserburg Facility

Recipharm’s new high speed filling line, designed for pre-filled syringes and cartridges, is expected to be operational by May 2023.

Recipharm, a global contract development and manufacturing organization, announced on Oct. 19, 2022 that it would be investing in a new high speed filling line for pre-filled syringes and cartridges at its sterile manufacturing facility in Wasserburg, Germany. The line, which is expected to be ready for its first good manufacturing practice batch run in May 2023, will be fully Annex 1 compliant and is designed to support both small and large volume projects.

According to a company press release, this decision was made as a result of increased customer demand in high growth fill formats. The Wasserburg facility specializes in producing more complex formats, ranging from lyophilization technology to aseptic filling into vials, syringes, and cartridges.

“The demand for pre-filled syringes is rapidly growing, with the projected market value by 2030 expecting to reach $6.5 billion,” said Marc Funk, CEO, Recipharm, in the release. “We are proud to be able to offer such a comprehensive service to our customers spanning device design, development and manufacturing to drug product fill & finish, and look forward to continuing to simplify the journey to market for our customers and of course helping patients access vital medicines.”

Source: Recipharm


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.